The global regenerative medicine market size reached USD 9.80 Billion in 2021 and is expected to reach USD 37.10 Billion in 2030 registering a CAGR of 15.9% during the forecast period, according to latest analysis by Emergen Research.
The global regenerative medicine market size reached USD 9.80 Billion in 2021 and is expected to reach USD 37.10 Billion in 2030 registering a CAGR of 15.9% during the forecast period, according to latest analysis by Emergen Research. Historical data suggests that the regenerative medicine market has been growing at a moderate pace in recent years. However, the COVID-19 pandemic is expected to have a significant impact on the growth of the market in 2020 and 2021. The market is expected to witness strong growth in the forecast period owing to rising government initiatives and investments in regenerative medicine research, falling costs of cell and gene therapies, and increasing commercialization of regenerative medicine products.
Rising government initiatives and investments in regenerative medicine research are expected to drive the growth of the market. Initiatives such as the National Institutes of Health’s Regenerative Medicine Program and the U.S. Food and Drug Administration’s (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation program are expected to create a favorable environment for the development and commercialization of regenerative medicine products. In addition, government agencies in Europe are also investing heavily in regenerative medicine research, which is expected to drive the growth of the market in the region.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/9
Falling costs of cell and gene therapies are expected to fuel the growth of the market. The costs of CAR T-cell therapy and gene therapy have been declining rapidly in recent years, owing to advances in manufacturing processes and technology. For instance, the cost of manufacturing Kymriah, a CAR T-cell therapy developed by Novartis, has declined from USD 1 million per treatment in 2017 to USD 300,000 per treatment in 2019. Similarly, the cost of manufacturing Zolgensma, a gene therapy developed by Novartis, has declined from USD 4 million per treatment in 2018 to USD 2.1 million in 2019.
The commercialization of regenerative medicine products is expected to drive the growth of the market. Currently, there are over 1,000 regenerative medicine clinical trials being conducted globally, and a large number of these products are expected to be commercialized in the next few years. In addition, several cell and gene therapies have been approved by regulatory agencies in recent years, which is expected to boost the growth of the market. For instance, in 2017, the FDA approved Kymriah, a CAR T-cell therapy developed by Novartis, for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in patients up to 25 years of age. Similarly, in 2019, the FDA approved Yescarta, a CAR T-cell therapy developed by Kite Pharma, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Some Key Highlights From the Report
- Regenerative medicine includes various therapeutic approaches to repair or replace damaged cells, tissues, and organs. It helps in curing several incurable diseases such as diabetes, Alzheimer’s disease, Parkinson’s disease, congestive heart failure (CHF), and others.
- The oncology segment accounted for largest revenue share in 2021 due to rise in number of cancer patients worldwide and increase in funding for cancer research. According to National Cancer Institute, in 2018, there were 1.7 million new cancer cases and 609,640 deaths due to cancer in the U.S.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/regenerative-medicine-market
- According to World Health Organization (WHO), globally, around 9.6 million people died due to cancer in 2018. Of these, around 60% of the deaths occurred in low- and middle-income countries. According to the same source, cancer is the second leading cause of death globally.
- According to the American Cancer Society, around 1,762,450 new cancer cases are expected to be diagnosed in 2019 in the U.S. Of these, around 606,880 people are expected to die due to cancer.
- The tissue engineering segment accounted for a moderate revenue share in 2021 due to the increasing adoption of mesenchymal stem cells and growth factors in the treatment of degenerative diseases. In addition, the therapeutic applications of 3D bioprinting in orthopedic and cardiovascular disorders are expected to fuel the segments market growth over the forecast period.
- The cell-based immunotherapy segment accounted for a significant revenue share in 2021 due to the large number of approvals for CAR-T therapies and the high demand from the oncology sector. Also, the growing demand for gene therapies is projected to boost the growth of this segment during the forecast period.
- The small molecule therapeutics segment is expected to register significant growth over the forecast period due to their wide range of applications in various therapeutic areas and the increasing number of clinical trials.
- North America held a significant revenue share in 2021 and is expected to maintain its leading position during the forecast period. The large presence of key market players and the high demand for advanced therapeutics are the key factors driving the growth of this region.
- Europe is expected to witness significant growth during the forecast period due to the increasing government support for regenerative medicine research and the growing number of clinical trials.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/9
Emergen Research has segmented global regenerative medicine market based on type, application, end-use, and region:
- Type Outlook (Revenue, USD Billion; 2019–2030)
- Gene Therapy
- Cell-based Immunotherapy
- Tissue Engineering
- Stem-cell Therapy
- Others
- Application Outlook (Revenue, USD Billion; 2019–2030)
- Oncology
- Musculoskeletal Disorders
- Infectious Diseases
- Cardiovascular Disorders
- Neurodegenerative Disorders
- Others
- End-Use Outlook (Revenue, USD Billion; 2019–2030)
- Hospitals & Clinics
- Commercial Industries
- Government & Academic Research Institutes
- Regional Outlook (Revenue, USD Billion; 2019-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of Middle East & Africa
- North America
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/9
Explore More Reports Emergen Research:
Spinal Implants and Surgery Devices Market
Operating Room Management Solutions Market
Business Intelligence and Analytics Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Press Release: https://www.emergenresearch.com/press-release/global-regenerative-medicine-market
Read blog Article: https://www.emergenresearch.com/blog/regenerative-medicine-market-driven-by-growing-application
Read our Special Article: https://www.emergenresearch.com/blog/stem-cell-therapy-market-drivers
Explore Our Custom Intelligence services | Growth Consulting Services
Latest Published Titles Smart Cities Market | Smart Learning Market
Trending Titles Humanoid Robot Market | Incident Response Market